Advertisement

A case of acute kidney injury secondary to black cherry concentrate in a patient with chronic kidney disease secondary to type 2 diabetes mellitus

  • Mohamad MatoutEmail author
  • Alex S. Halme
  • Jeffrey Wiseman
Case Report
  • 23 Downloads

Abstract

There are many herbal products which are accessible to patients, and they may provide with many health benefits. Nevertheless, some of these supplements can lead to significant morbidity as they can also have important side effects and impact patient’s organ systems. In this case report, we present a patient with chronic kidney disease secondary to type II diabetes mellitus who develops acute kidney injury and metabolic disturbances secondary to consuming black cherry concentrate as a mean to self-manage his gout flare. The most likely mechanism of injury was cyclooxygenase inhibition by anthocyanins, molecular compounds found in cherries that have a similar mechanism of action to nonsteroidal anti-inflammatory medications. Patient’s kidney injury and metabolic disturbances improved after the discontinuation of black cherry concentrate. This is the second case report that presents a correlation between consumption of cherry concentrate in a patient with chronic kidney disease and acute kidney injury.

Keywords

Acute kidney injury Herbal medicine Chronic kidney disease Anthocyanins 

Notes

References

  1. 1.
    ONTARGET. Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. U.S. National Library of Medicine. 2008. Retrieved December 10, 2017, from ​https://www.ncbi.nlm.nih.gov/pubmed/18378520
  2. 2.
    Kalra EK. Nutraceutical—definition and introduction. AAPS PharmSci. 2003;5:E25.CrossRefGoogle Scholar
  3. 3.
    McCune LM, Kubota C, Stendell-Hollis NR, Thomson CA. Cherries and health: a review. Crit Rev Food Sci Nutr (Informa UK Limited). 2010;51(1):1–12.  https://doi.org/10.1080/2F10408390903001719.CrossRefGoogle Scholar
  4. 4.
    Blau LW. Cherry diet control for gout and arthritis. Tex Rep Biol Med. 1950;8:309–11.Google Scholar
  5. 5.
    Jacob RA, Spinozzi GM, Simon VA, Kelley DS, Prior RL, Hess-Pierce B, et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003;133:1826–9.CrossRefGoogle Scholar
  6. 6.
    Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi HK. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 2012;64:4004–11.CrossRefGoogle Scholar
  7. 7.
    Aherne SA, O’Brien NM. Dietary flavonols: chemistry, food content, and metabolism. Nutrition. 2002;18:75–81.CrossRefGoogle Scholar
  8. 8.
    Duthie GG, Duthie SJ, Kyle JA. Plant polyphenols in cancer and heart disease: implications as nutritional antioxidants. Nutr Res Rev. 2000;13:79–106.CrossRefGoogle Scholar
  9. 9.
    Mulabagal V, et al. Anthocyanin content, lipid peroxidation and cyclooxygenase enzyme inhibitory activities of sweet and sour cherries. J Agric Food Chem (U.S. National Library of Medicine). 2009. Retrieved December 10, 2017 from https://www.ncbi.nlm.nih.gov/pubmed/19199585.
  10. 10.
    Seeram NP, et al. Cyclooxygenase inhibitory and antioxidant cyanidin glycosides in cherries and berries. Phytomedicine (U.S. National Library of Medicine). 2001. Retrieved December 12, 2017 from https://www.ncbi.nlm.nih.gov/pubmed/11695879.
  11. 11.
    Vitale P, Panella A, Scilimati A, Perrone MG. COX-1 inhibitors: beyond structure toward therapy. Med Res Rev. 2016;36:641–71.CrossRefGoogle Scholar
  12. 12.
    Firestein GS. Mechanisms of inflammation and tissue repair. Goldmans Cecil Med (Elsevier BV). 2012.  https://doi.org/10.1016/2Fb978-1-4377-1604-7.00047-6.
  13. 13.
    Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. American College of Rheumatology guidelines for management of gout Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64:1447–61.CrossRefGoogle Scholar
  14. 14.
    Tulunay FC. NSAIDs: behind the mechanisms of action. Funct Neurol. 2000;15(Suppl 3):202–7.Google Scholar
  15. 15.
    Kirschenbaum A. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts. J Clin Endocrinol Metabol (The Endocrine Society). 2000;85(9):3436–41.  https://doi.org/10.1210/2Fjc.85.9.3436.Google Scholar
  16. 16.
    Walls, R. M., Hockberger, R. S., & Gausche-Hill, M. (2018). Aspirin and Nonsteroidal Agents. In: Rosens emergency medicine: Concepts and clinical practice. Philadelphia, PA: Elsevier.Google Scholar
  17. 17.
    McQuay HJ, Moore RA. NSAIDS and Coxibs: clinical use. In: Wall and Melzack's Textbook of Pain. Elsevier BV; 2006. p. 471–80.Google Scholar
  18. 18.
    Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.CrossRefGoogle Scholar
  19. 19.
    Luciano RL. Acute kidney injury from cherry concentrate in a patient with CKD. Am J Kidney Dis. 2014;63(3):503–5.  https://doi.org/10.1053/2Fj.ajkd.2013.09.021.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  1. 1.Faculty of MedicineMcGill UniversityMontrealCanada
  2. 2.McGill University Health Center, Department of MedicineMontrealCanada

Personalised recommendations